Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2024

Open Access 01-12-2024 | Research

Drivers of vulnerability to medicine smuggling and combat strategies: a qualitative study based on online news media analysis in Iran

Authors: NourolHoda Fakhrzad, Vahid Yazdi-Feyzabadi, Maryam Fakhrzad

Published in: BMC Health Services Research | Issue 1/2024

Login to get access

Abstract

Background

Medicine smuggling poses a serious public health threat, limiting patients’ safe and timely access to this essential resource. Thus, this study aims to identify the factors contributing to the vulnerability to medicine smuggling and propose effective strategies to combat this issue in Iran.

Methods

An analysis of news media was conducted using qualitative content analysis. News text items related to medicine smuggling were retrieved from various online news sources between March 21, 2017, and May 21, 2023. To select health-oriented and general online news stations, news agencies, and newspapers, the purposeful sampling method with a maximum variation strategy was used. The selected sources included Mehr News Agency, Khabar Online, Islamic Consultative Assembly News Agency (ICANA), Islamic Republic News Agency (IRNA), Iranian Students News Agency (ISNA), Hamshahri, Donya-e-Eqtesad newspapers, Webda, Sepid Online, and Iran’s Food and Drug Administration News Agency (IFDANA). All data coding was manually done using Microsoft Excel software version 2016.

Results

A total of 277 news articles were found to meet the established criteria for inclusion. The analysis revealed four main themes, each with several sub-themes, that shed light on the factors that drive vulnerability and the strategies to combat medicine smuggling. These themes are the economic environment, government and stewardship, information technology systems, and socio-cultural factors. The economic environment emerged as the most significant theme, encompassing medicine selection, reimbursement, and procurement, all of which affect the smuggling of pharmaceuticals in Iran.

Conclusion

To combat medicine smuggling, it is important to adjust policies based on the identified vulnerabilities. Effective strategies to reverse pharmaceutical smuggling include capacity building of pharmaceutical manufacturing companies, implementing regulated and enhanced supervisory and rulemaking policies, strengthening health insurance, improving e-infrastructure, and increasing public awareness through collaborative approaches involving various stakeholders within and outside the health system.
Appendix
Available only for authorised users
Literature
1.
Roumina E. Theoretical explanation of Imported Good Smuggling and its management. Geopolitics Q. 2014;10(33):83–105.
2.
Ansari M, Takian A, Yazdi-Feyzabadi V. The challenges of Iran’s Pharmaceutical Export: a qualitative content analysis. Management and Economics: Evidence-Based Health Policy; 2022.
3.
Shaw M, Reitano T, Haysom S, Tinti P. States on the cusp: Overcoming illicit trade’s corrosive effects in developing economies. 2020 October 23, 2020.
4.
Miraglia P, Ochoa R, Briscoe I. Transnational organised crime and fragile states. 2012.
5.
Zeiler I, Sallusti F, Kamprad A, Bisogno E. Measuring illegal economic activities and illicit financial flows: challenges and possible solutions. indicator. 2019;16:1.
6.
Ozawa S, Higgins CR, Yemeke TT, Nwokike JI, Evans L, Hajjou M, et al. Importance of medicine quality in achieving universal health coverage. PLoS ONE. 2020;15(7):e0232966.PubMedPubMedCentralCrossRef
7.
8.
9.
Eini M. Criminal combating the Counterfeiting of Medical Products in International instruments and Iranian Law. Comp Law Rev. 2021;12(1):263–89.
10.
Pathak R, Gaur V, Sankrityayan H, Gogtay J. Tackling Counterfeit drugs: the challenges and possibilities. Pharm Med. 2023:1–10.
11.
Davari M, Walley T, Haycox A. Pharmaceutical policy and market in Iran: past experiences and future challenges. J Pharm Health Serv Res. 2011;2(1):47–52.CrossRef
12.
Olyaaeemanesh A, Jaafaripooyan E, Abdollahiasl A, Davari M, Mousavi SM, Delpasand M. Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis. Health Res Policy Syst. 2021;19:1–17.CrossRef
13.
Zarif-Yeganeh M, Kargar M, Rashidian A, Kohneloo AJ, Gholami K. Out-of-pocket payment and affordability of medication for geriatric patients in Tehran, Iran. Iran J Public Health. 2019;48(6):1124.PubMedPubMedCentral
14.
Gaudiano MC, Manna L, Bartolomei M, Rodomonte AL, Bertocchi P, Antoniella E, et al. Health risks related to illegal and online sale of drugs and food supplements: results of a survey on marketed products in Italy from 2011 to 2013. Annali dell’Istituto Superiore Di Sanitą. 2016;52(1):128–32.PubMed
15.
Sardela VF, Carvalho AR, Nunes IKC. The black market for anorectic agents: a case study of amfepramone. Toxicol Anal et Clinique. 2018;30(2):149–53.CrossRef
16.
Ting CY, Ting H, Soh YC, Aaj AH, Lee KS. Awareness of customs officers on counterfeit pharmaceutical products and the roles of pharmacy enforcement officers. J Young Pharmacists. 2017;9(2):258.CrossRef
17.
Fotiou F, Aravind S, Wang PP, Nerapusee O. Impact of illegal trade on the quality of epoetin alfa in Thailand. Clin Ther. 2009;31(2):336–46.PubMedCrossRef
18.
Garuba HA, Kohler JC, Huisman AM. Transparency in Nigeria’s public pharmaceutical sector: perceptions from policymakers. Globalization Health. 2009;5:1–13.CrossRef
19.
Mackey TK, Liang BA. The global counterfeit drug trade: patient safety and public health risks. J Pharm Sci. 2011;100(11):4571–9.PubMedCrossRef
20.
Alizadeh Sameh S, PourQahramani B. Recognition of effective factors in the fight against drug trafficking. Q J Intell Criminal Res. 2019;14(2):9–26.
21.
Janparvar M, Qasri M. Explaining the factors affecting the smuggling of goods across borders the initial strategy of border management in Iran. J Disciplinary Geogr. 2014;2(7):55–86.
22.
Kim D, Tajima Y. Smuggling and border enforcement. Int Org. 2022;76(4):830–67.CrossRef
23.
Dégardin K, Roggo Y, Margot P. Understanding and fighting the medicine counterfeit market. J Pharm Biomed Anal. 2014;87:167–75.PubMedCrossRef
24.
Hosseini S, Darbooy S, Banihashemi ST, Naseri S, Dinarvand R. Counterfeit medicines: report of a cross-sectional retrospective study in Iran. Public Health. 2011;125(3):165–71.PubMedCrossRef
25.
Fatemi Moghaddam S. Investigating the failure of drug distribution companies to reform the distribution system and reduce drug trafficking. International Conference of Management Elites. 2016;1.
26.
Macnamara JR. Media content analysis: its uses, benefits and best practice methodology. Asia Pac Public Relations J. 2005;6(1):1–34.
27.
Ashoorkhani M, Gholami J, Maleki K, Nedjat S, Mortazavi J, Majdzadeh R. Quality of health news disseminated in the print media in developing countries: a case study in Iran. BMC Public Health. 2012;12(1):1–7.CrossRef
28.
Kheirandish M, Rashidian A, Bigdeli M. A news media analysis of economic sanction effects on access to medicine in Iran. J Res Pharm Pract. 2015;4(4):199.PubMedPubMedCentralCrossRef
29.
Webster F, Rice K, Sud A. A critical content analysis of media reporting on opioids: the social construction of an epidemic. Soc Sci Med. 2020;244:112642.PubMedCrossRef
30.
Thomas T, Wilson A, Tonkin E, Miller ER, Ward PR. How the media places responsibility for the COVID-19 pandemic—An Australian media analysis. Front Public Health. 2020;8:483.PubMedPubMedCentralCrossRef
31.
Islam MS, Sarkar T, Khan SH, Kamal A-HM, Hasan SM, Kabir A, et al. COVID-19–related infodemic and its impact on public health: a global social media analysis. Am J Trop Med Hyg. 2020;103(4):1621.PubMedPubMedCentralCrossRef
32.
Denecke K, Nejdl W. How valuable is medical social media data? Content analysis of the medical web. Inf Sci. 2009;179(12):1870–80.CrossRef
33.
Tyrawski J, DeAndrea DC. Pharmaceutical companies and their drugs on social media: a content analysis of drug information on popular social media sites. J Med Internet Res. 2015;17(6):e130.PubMedPubMedCentralCrossRef
34.
Zare-Farashbandi F, Amini F, Rahimi A, Kelishadi R. A content analysis of pediatric information in widely circulated newspapers in Iran. J Educ Health Promotion. 2017;6.
35.
Farashbandi FZ, Amini F, Rahimi A, Kelishadi R. A content analysis of pediatric information in widely circulated newspapers in Iran. Payesh (Health Monitor). 2017;16(2):180–9.
36.
37.
Danaei G, Farzadfar F, Kelishadi R, Rashidian A, Rouhani OM, Ahmadnia S et al. Review Iran in transition.
38.
Bazyar M, Rashidian A, Kane S, Mahdavi MRV, Sari AA, Doshmangir L. Policy options to reduce fragmentation in the pooling of health insurance funds in Iran. Int J Health Policy Manage. 2016;5(4):253.CrossRef
39.
Cheraghali AM. Current status of biopharmaceuticals in Iran’s pharmaceutical market. Generics Biosimilars Initiative J. 2013;2(1):26–31.CrossRef
40.
41.
Zaboli P, Hashemi-Meshkini A, Varmaghani M, Gholami H, Vazirian I, Zekri H-S, et al. Pharmaceutical laws and regulations in Iran: an overview. J Res Pharm Pract. 2016;5(3):155.PubMedPubMedCentralCrossRef
42.
CHERAGHALI A. Pharmacoeconomics: an effective tool for prioritization in Iran’s healthcare system. 2008.
43.
44.
Kadkhodamanesh A, Varahrami V, Zarei L, Peiravian F, Hadidi M, Yousefi N. Investigation the determinants of pharmaceutical expenditure share of GDP in Iran and selected OECD countries. J Pharm Policy Pract. 2021;14(1):1–10.CrossRef
45.
Ministry of Health of Iran. Iranian pharmaceutical statistical datasheet. Food and Drug Administration, various issues 2018 [Available from: www.​fda.​gov.​ir/​en.
46.
Dinarvand R. New national drug policy in Iran leading to expanded pharmaceutical market and extended access of the public to medicines. 2009.
47.
Mensa Sorato M, Davari M, Abdollahi Asl A, Soleymani F, Kebriaeezadeh A. Why healthcare market needs government intervention to improve access to essential medicines and healthcare efficiency: a scoping review from pharmaceutical price regulation perspective. J Pharm Health Serv Res. 2020;11(4):321–33.CrossRef
48.
Soltani M, Minaei H, Rahim M, Motevali Khameneh M. Assessing the situation of pharmaceutical raw material production industry in Iran in terms of market supply, valuation, production depth, technology level, and price of products. 2021.
49.
50.
Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77–101.CrossRef
51.
Cypress BS. Rigor or reliability and validity in qualitative research: perspectives, strategies, reconceptualization, and recommendations. Dimens Crit Care Nurs. 2017;36(4):253–63.PubMedCrossRef
52.
Shahmirzadi NA, Abdollahiasl A, Kebriaeezadeh A. Assessment of influential variables in the pricing of locally manufactured pharmaceuticals: current Challenging Situation in Iran. Iran J Pharm Research: IJPR. 2021;20(1):283.
53.
Bastani P, Dehghan Z, Kashfi SM, Dorosti H, Mohammadpour M, Mehralian G. Challenge of politico-economic sanctions on pharmaceutical procurement in Iran: a qualitative study. Iran J Med Sci. 2022;47(2):152.PubMedPubMedCentral
54.
Esfandiari A, Yazdi-Feyzabadi V, Zarei L, Rashidian A, Salari H. Transparency in the public pharmaceutical sector: the key informants’ perceptions from a developing country. BMC Health Serv Res. 2021;21:1–18.CrossRef
55.
Abdoulaye I, Chastanier H, Azondekon A, Dansou A, Bruneton C. Survey on the illicit drug market in Cotonou, Benin in March 2003. Med Tropicale: Revue Du Corps De Sante Colonial. 2006;66(6):573–6.
56.
Dagrou A, Chimhutu V, I Buy Medicines From the Streets Because I Am Poor. A qualitative account on why the Informal Market for Medicines Thrive in Ivory Coast. INQUIRY: J Health Care Organ Provis Financing. 2022;59:00469580221086585.
57.
Vande Walle G, Ponsaers P. Formal and informal pharmaceutical economies in Third World countries: Synergetic, symbiotic or parasitical? Crime law Social Change. 2006;45:361–72.CrossRef
58.
Mackey TK, Cuomo RE. An interdisciplinary review of digital technologies to facilitate anti-corruption, transparency, and accountability in medicines procurement. Global Health Action. 2020;13(sup1):1695241.PubMedPubMedCentralCrossRef
59.
Baghdadi-Sabeti G, Serhan F. WHO Good Governance for Medicines program: an innovative approach to prevent corruption in the pharmaceutical sector. Geneva: World Health Organization; 2010.
60.
Abdoulaye I, Chastanier H, Azondekon A, Dansou A, Bruneton C. Evaluation des campagnes de sensibilisation sur les pratiques d’achat de médicaments dans la ville de Cotonou. Médecine Tropicale. 2006;66(6):615.PubMed
61.
Tian Y, Reichardt B, Dunkler D, Hronsky M, Winkelmayer WC, Bucsics A, et al. Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study. Sci Rep. 2020;10(1):5964.PubMedPubMedCentralCrossRef
62.
Alshakka M, Mohamed Ibrahim MI, Bahattab A, Badulla WF, Shankar PR. An insight into the pharmaceutical sector in Yemen during conflict: challenges and recommendations. Med Confl Survival. 2020;36(3):232–48.CrossRef
63.
Bashir A, Galal S, Ramadan A, Wahdan A, El-Khordagui L. Community pharmacists’ perceptions, awareness and practices regarding counterfeit medicines: a cross-sectional survey in Alexandria, Egypt. East Mediterr Health J. 2020;26(5):556–64.PubMedCrossRef
64.
Gutorova NO, Pashkov VM, Soloviov OS. Illegal internet pharmacies as a threat to public health in Europe. Wiad Lek. 2021;74(9):2169–74.PubMedCrossRef
Metadata
Title
Drivers of vulnerability to medicine smuggling and combat strategies: a qualitative study based on online news media analysis in Iran
Authors
NourolHoda Fakhrzad
Vahid Yazdi-Feyzabadi
Maryam Fakhrzad
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2024
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-024-10805-7

Other articles of this Issue 1/2024

BMC Health Services Research 1/2024 Go to the issue

Research

A stakeholder analysis to prepare for real-world evaluation of integrating artificial intelligent algorithms into breast screening (PREP-AIR study): a qualitative study using the WHO guide

Research

“You get out of the house, you talk to each other, you laugh…And that’s fantastic” – a qualitative study about older people’s perceptions of social prescribing in mainland Portugal

Research

Palliative care patients in the emergency medical service: a retrospective cohort study from Finland

Research

Evaluating implementation of a community-focused patient navigation intervention at an NCI-designated cancer center using RE-AIM

Research

Increasing and sustaining discharges by noon – a multi-year process improvement project

Research

Commercial provider staff experiences of the NHS low calorie diet programme pilot: a qualitative exploration of key barriers and facilitators